Natural products to drugs: natural product-derived compounds in clinical trials

Natural product and natural product-derived compounds that are being evaluated in clinical trials or are in registration (as at 31st December 2007) have been reviewed, as well as natural product-derived compounds for which clinical trials have been halted or discontinued since 2005. Also discussed a...

Full description

Saved in:
Bibliographic Details
Published in:Natural product reports 2008-01, Vol.25 (3), p.475-516
Main Author: Butler, Mark S
Format: Article
Language:English
Subjects:
Biological Products - chemistry
Biological Products - pharmacology
Clinical Trials as Topic
Drug Industry - trends
Molecular Structure
Pharmaceutical Preparations - chemistry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c367t-1bcddd4a2b3633d27be3cfe96c6b9d960ff7a0ffbb846b4b601ce42c0afc68043
cites cdi_FETCH-LOGICAL-c367t-1bcddd4a2b3633d27be3cfe96c6b9d960ff7a0ffbb846b4b601ce42c0afc68043
container_end_page 516
container_issue 3
container_start_page 475
container_title Natural product reports
container_volume 25
creator Butler, Mark S
description Natural product and natural product-derived compounds that are being evaluated in clinical trials or are in registration (as at 31st December 2007) have been reviewed, as well as natural product-derived compounds for which clinical trials have been halted or discontinued since 2005. Also discussed are natural product-derived drugs launched since 2005, new natural product templates and late-stage development candidates.
doi_str_mv 10.1039/b514294f
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70765487</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70765487</sourcerecordid><originalsourceid>FETCH-LOGICAL-c367t-1bcddd4a2b3633d27be3cfe96c6b9d960ff7a0ffbb846b4b601ce42c0afc68043</originalsourceid><addsrcrecordid>eNpVkEtLAzEUhYMotlbBXyBZiZvRZJK5mbiT4guK3eh6yFMi86jJRPDfd6QVcXPP4n4cDh9C55RcU8Lkja4oLyX3B2hOOZCCi6o8RHNSQlWQCuoZOknpgxBKBcAxmtGaS1FLmKP1ixpzVC3exMFmMyY8DtjG_J5ucf__VVgXw5ez2AzdZsi9TTj02LShD2aixhhUm07RkZ_Cne1zgd4e7l-XT8Vq_fi8vFsVhoEYC6qNtZarUjNgzJZCO2a8k2BASyuBeC_UdLSuOWiugVDjeGmI8gZqwtkCXe56p3Gf2aWx6UIyrm1V74acGkEEVLwWE3i1A00cUorON5sYOhW_G0qaH3nNr7wJvdh3Zt05-wfubbEtRytrqw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70765487</pqid></control><display><type>article</type><title>Natural products to drugs: natural product-derived compounds in clinical trials</title><source>Royal Society of Chemistry</source><creator>Butler, Mark S</creator><creatorcontrib>Butler, Mark S</creatorcontrib><description>Natural product and natural product-derived compounds that are being evaluated in clinical trials or are in registration (as at 31st December 2007) have been reviewed, as well as natural product-derived compounds for which clinical trials have been halted or discontinued since 2005. Also discussed are natural product-derived drugs launched since 2005, new natural product templates and late-stage development candidates.</description><identifier>ISSN: 0265-0568</identifier><identifier>EISSN: 1460-4752</identifier><identifier>DOI: 10.1039/b514294f</identifier><identifier>PMID: 18497896</identifier><language>eng</language><publisher>England</publisher><subject>Biological Products - chemistry ; Biological Products - pharmacology ; Clinical Trials as Topic ; Drug Industry - trends ; Molecular Structure ; Pharmaceutical Preparations - chemistry</subject><ispartof>Natural product reports, 2008-01, Vol.25 (3), p.475-516</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c367t-1bcddd4a2b3633d27be3cfe96c6b9d960ff7a0ffbb846b4b601ce42c0afc68043</citedby><cites>FETCH-LOGICAL-c367t-1bcddd4a2b3633d27be3cfe96c6b9d960ff7a0ffbb846b4b601ce42c0afc68043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18497896$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Butler, Mark S</creatorcontrib><title>Natural products to drugs: natural product-derived compounds in clinical trials</title><title>Natural product reports</title><addtitle>Nat Prod Rep</addtitle><description>Natural product and natural product-derived compounds that are being evaluated in clinical trials or are in registration (as at 31st December 2007) have been reviewed, as well as natural product-derived compounds for which clinical trials have been halted or discontinued since 2005. Also discussed are natural product-derived drugs launched since 2005, new natural product templates and late-stage development candidates.</description><subject>Biological Products - chemistry</subject><subject>Biological Products - pharmacology</subject><subject>Clinical Trials as Topic</subject><subject>Drug Industry - trends</subject><subject>Molecular Structure</subject><subject>Pharmaceutical Preparations - chemistry</subject><issn>0265-0568</issn><issn>1460-4752</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNpVkEtLAzEUhYMotlbBXyBZiZvRZJK5mbiT4guK3eh6yFMi86jJRPDfd6QVcXPP4n4cDh9C55RcU8Lkja4oLyX3B2hOOZCCi6o8RHNSQlWQCuoZOknpgxBKBcAxmtGaS1FLmKP1ixpzVC3exMFmMyY8DtjG_J5ucf__VVgXw5ez2AzdZsi9TTj02LShD2aixhhUm07RkZ_Cne1zgd4e7l-XT8Vq_fi8vFsVhoEYC6qNtZarUjNgzJZCO2a8k2BASyuBeC_UdLSuOWiugVDjeGmI8gZqwtkCXe56p3Gf2aWx6UIyrm1V74acGkEEVLwWE3i1A00cUorON5sYOhW_G0qaH3nNr7wJvdh3Zt05-wfubbEtRytrqw</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>Butler, Mark S</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080101</creationdate><title>Natural products to drugs: natural product-derived compounds in clinical trials</title><author>Butler, Mark S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c367t-1bcddd4a2b3633d27be3cfe96c6b9d960ff7a0ffbb846b4b601ce42c0afc68043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Biological Products - chemistry</topic><topic>Biological Products - pharmacology</topic><topic>Clinical Trials as Topic</topic><topic>Drug Industry - trends</topic><topic>Molecular Structure</topic><topic>Pharmaceutical Preparations - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Butler, Mark S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Natural product reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Butler, Mark S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Natural products to drugs: natural product-derived compounds in clinical trials</atitle><jtitle>Natural product reports</jtitle><addtitle>Nat Prod Rep</addtitle><date>2008-01-01</date><risdate>2008</risdate><volume>25</volume><issue>3</issue><spage>475</spage><epage>516</epage><pages>475-516</pages><issn>0265-0568</issn><eissn>1460-4752</eissn><abstract>Natural product and natural product-derived compounds that are being evaluated in clinical trials or are in registration (as at 31st December 2007) have been reviewed, as well as natural product-derived compounds for which clinical trials have been halted or discontinued since 2005. Also discussed are natural product-derived drugs launched since 2005, new natural product templates and late-stage development candidates.</abstract><cop>England</cop><pmid>18497896</pmid><doi>10.1039/b514294f</doi><tpages>42</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0265-0568
ispartof Natural product reports, 2008-01, Vol.25 (3), p.475-516
issn 0265-0568
1460-4752
language eng
recordid cdi_proquest_miscellaneous_70765487
source Royal Society of Chemistry
subjects Biological Products - chemistry
Biological Products - pharmacology
Clinical Trials as Topic
Drug Industry - trends
Molecular Structure
Pharmaceutical Preparations - chemistry
title Natural products to drugs: natural product-derived compounds in clinical trials
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A09%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Natural%20products%20to%20drugs:%20natural%20product-derived%20compounds%20in%20clinical%20trials&rft.jtitle=Natural%20product%20reports&rft.au=Butler,%20Mark%20S&rft.date=2008-01-01&rft.volume=25&rft.issue=3&rft.spage=475&rft.epage=516&rft.pages=475-516&rft.issn=0265-0568&rft.eissn=1460-4752&rft_id=info:doi/10.1039/b514294f&rft_dat=%3Cproquest_cross%3E70765487%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c367t-1bcddd4a2b3633d27be3cfe96c6b9d960ff7a0ffbb846b4b601ce42c0afc68043%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=70765487&rft_id=info:pmid/18497896&rfr_iscdi=true